Compare ALEC & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALEC | ARCT |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.6M | 163.4M |
| IPO Year | 2019 | 2019 |
| Metric | ALEC | ARCT |
|---|---|---|
| Price | $2.45 | $15.81 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $4.83 | ★ $24.11 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | $21,045,000.00 | ★ $82,031,000.00 |
| Revenue This Year | $2.03 | N/A |
| Revenue Next Year | $29.87 | $12.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.09 | $5.50 |
| 52 Week High | $3.40 | $24.14 |
| Indicator | ALEC | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.83 | 70.15 |
| Support Level | $1.93 | $6.47 |
| Resistance Level | $2.58 | N/A |
| Average True Range (ATR) | 0.22 | 1.60 |
| MACD | 0.02 | 0.35 |
| Stochastic Oscillator | 76.16 | 76.36 |
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.